Bader T, Zoumakis E, Friedberg M, Hiroi N, Chrousos G P, Hochberg Z
Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, MD, USA.
Horm Metab Res. 2002 Nov-Dec;34(11-12):752-7. doi: 10.1055/s-2002-38255.
In humans, oxoreducing 11beta-HSD-1 activity appears to be related to body fat distribution in male-type central obesity, but not in female-type peripheral obesity. We postulated that inhibition of 11beta-HSD-1 might have clinical therapeutic significance in oxoreducing mostly visceral fat and its metabolic activity. Our current study investigated the consequence at the cellular level of such inhibition. As an inhibitor of 11beta-HSD-1 activity, we used the licorice derivative carbenoxolone. Carbenoxolone has an inhibitory effect on the activity of both oxidizing 11beta-HSD-2, which converts cortisol to cortisone, and oxoreducing 11beta-HSD-1; yet, preadipocytes and adipocytes only express the latter. Preadipocytes were retrieved from omental and subcutaneous fat from healthy non-obese individuals and differentiated in vitro to mature adipocytes. Activity of 11beta-HSD-1 was assayed by measuring conversion of added 500 nM cortisone to cortisol. Expression of 11beta-HSD-1 mRNA was determined by real-time PCR, while lipolytic effects were determined by measuring glycerol and triglyceride concentration in the culture medium. Carbenoxolone decreased 11beta-HSD-1 activity in a dose-dependent manner with an IC-50 of 5X10 -6 M, but did not affect the expression of 11beta-HSD-1 mRNA. Cortisone stimulated subcutaneous, but not omental preadipocytes proliferation, an effect that was not abolished by carbenoxolone. Dexamethasone had a stimulatory effect on the maturation of both omental and subcutaneous preadipocytes. Carbenoxolone per se, either with or without cortisone, had a negative effect on preadipocyte maturation. Inhibiting 11beta-HSD-1 activity by carbenoxolone had no impact on leptin secretion. Thus, carbenoxolone has no effect on preadipocyte proliferation, but a dramatic inhibitory effect on preadipocyte differentiation into mature adipocytes. The mechanism is only partly related to its inhibitory effect on 11beta-HSD-1 activity. The present observations lend support to the presence of an intracrine loop of a hormone that is both produced from a precursor and active within the preadipocyte and adipocyte.
在人类中,氧化还原型11β-羟基类固醇脱氢酶1(11β-HSD-1)的活性似乎与男性型中心性肥胖的体脂分布有关,但与女性型外周性肥胖无关。我们推测,抑制11β-HSD-1可能对主要减少内脏脂肪及其代谢活性具有临床治疗意义。我们目前的研究在细胞水平上研究了这种抑制的后果。作为11β-HSD-1活性的抑制剂,我们使用了甘草衍生物生胃酮。生胃酮对将皮质醇转化为可的松的氧化型11β-HSD-2和氧化还原型11β-HSD-1的活性均有抑制作用;然而,前脂肪细胞和脂肪细胞仅表达后者。从健康非肥胖个体的网膜和皮下脂肪中获取前脂肪细胞,并在体外将其分化为成熟脂肪细胞。通过测量添加的500 nM可的松向皮质醇的转化来测定11β-HSD-1的活性。通过实时PCR测定11β-HSD-1 mRNA的表达,同时通过测量培养基中甘油和甘油三酯的浓度来确定脂解作用。生胃酮以剂量依赖性方式降低11β-HSD-1活性,IC-50为5×10 -6 M,但不影响11β-HSD-1 mRNA的表达。可的松刺激皮下前脂肪细胞增殖,但不刺激网膜前脂肪细胞增殖,生胃酮并未消除这种作用。地塞米松对网膜和皮下前脂肪细胞的成熟均有刺激作用。生胃酮本身,无论有无可的松,对前脂肪细胞成熟均有负面影响。生胃酮抑制11β-HSD-1活性对瘦素分泌没有影响。因此,生胃酮对前脂肪细胞增殖没有影响,但对前脂肪细胞分化为成熟脂肪细胞有显著抑制作用。其机制仅部分与其对11β-HSD-1活性的抑制作用有关。目前的观察结果支持存在一种激素的自分泌环,该激素由前体产生并在前脂肪细胞和脂肪细胞内具有活性。